Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Insider: 89Bio, Aprea among week's notable insider trades » 12:40
07/13/20
07/13
12:40
07/13/20
12:40
ETNB

89bio

$33.16 /

+0.78 (+2.41%)

, VCNX

Vaccinex

$4.81 /

+0.86 (+21.77%)

, WTI

W&T Offshore

$2.36 /

+0.055 (+2.39%)

, COO

Cooper Companies

$288.19 /

-1.02 (-0.35%)

, SYNH

Syneos Health

$57.99 /

+1.58 (+2.80%)

, ADPT

Adaptive Biotechnologies

$47.00 /

+1.04 (+2.26%)

, ALNY

Alnylam

$161.08 /

-1.25 (-0.77%)

, BILL

Bill.com

$90.35 /

+0.66 (+0.74%)

, CIEN

Ciena

$54.81 /

-0.17 (-0.31%)

, APRE

Aprea Therapeutics

$29.35 /

-0.12 (-0.41%)

Welcome to "Fly Insider,"…

Open Full Text

ShowHide Related Items >><<
WTI W&T Offshore
$2.36 /

+0.055 (+2.39%)

VCNX Vaccinex
$4.81 /

+0.86 (+21.77%)

SYNH Syneos Health
$57.99 /

+1.58 (+2.80%)

ETNB 89bio
$33.16 /

+0.78 (+2.41%)

COO Cooper Companies
$288.19 /

-1.02 (-0.35%)

CIEN Ciena
$54.81 /

-0.17 (-0.31%)

BILL Bill.com
$90.35 /

+0.66 (+0.74%)

APRE Aprea Therapeutics
$29.35 /

-0.12 (-0.41%)

ALNY Alnylam
$161.08 /

-1.25 (-0.77%)

ADPT Adaptive Biotechnologies
$47.00 /

+1.04 (+2.26%)

ETNB 89bio
$33.16 /

+0.78 (+2.41%)

07/07/20 Chardan
89bio initiated with a Buy at Chardan
12/09/19 Oppenheimer
89bio initiated with an Outperform at Oppenheimer
12/09/19 SVB Leerink
89bio initiated with an Outperform at SVB Leerink
12/09/19 RBC Capital
89bio initiated with an Outperform at RBC Capital
VCNX Vaccinex
$4.81 /

+0.86 (+21.77%)

WTI W&T Offshore
$2.36 /

+0.055 (+2.39%)

04/17/20 Roth Capital
W&T Offshore upgraded to Buy from Neutral at Roth Capital
03/13/20 Roth Capital
W&T Offshore downgraded to Neutral from Buy at Roth Capital
03/09/20 Stifel
W&T Offshore downgraded to Hold from Buy at Stifel
COO Cooper Companies
$288.19 /

-1.02 (-0.35%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/06/20 Baird
Cooper Companies downgraded to Neutral from Outperform at Baird
06/05/20 UBS
UBS backs Buy on Alcon after Cooper results
05/26/20 Stephens
Cooper Companies price target raised to $325 from $300 at Stephens
SYNH Syneos Health
$57.99 /

+1.58 (+2.80%)

04/03/20 Mizuho
Syneos Health price target lowered to $42 from $56 at Mizuho
04/02/20 Credit Suisse
Syneos Health price target lowered to $62 from $72 at Credit Suisse
03/30/20 Goldman Sachs
Syneos Health downgraded to Neutral from Buy at Goldman Sachs
03/17/20 SunTrust
SunTrust cuts price targets across CROs, downgrades MedPace
ADPT Adaptive Biotechnologies
$47.00 /

+1.04 (+2.26%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
ALNY Alnylam
$161.08 /

-1.25 (-0.77%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
BILL Bill.com
$90.35 /

+0.66 (+0.74%)

06/29/20 Goldman Sachs
Bill.com price target raised to $90 from $60 at Goldman Sachs
05/28/20
Fly Intel: Top five analyst upgrades
05/28/20 Piper Sandler
Bill.com upgraded to Overweight from Neutral at Piper Sandler
05/18/20 KeyBanc
Bill.com price target raised to $85 from $76 at KeyBanc
CIEN Ciena
$54.81 /

-0.17 (-0.31%)

06/05/20 JPMorgan
JPMorgan ups Ciena target to $63 from $53, adds to Analyst Focus List
06/05/20 Stifel
Ciena price target raised to $61 from $54 at Stifel
06/05/20 Cowen
Ciena price target raised to $73 from $69 at Cowen
06/05/20 Barclays
Ciena price target raised to $67 from $48 at Barclays
APRE Aprea Therapeutics
$29.35 /

-0.12 (-0.41%)

06/22/20
Fly Intel: Top five analyst initiations
06/22/20 H.C. Wainwright
Aprea Therapeutics initiated with a Neutral at H.C. Wainwright
04/21/20
Fly Intel: Top five analyst initiations
04/20/20
Baird starts Aprea Therapeutics with Outperform on APR-246 potential
WTI W&T Offshore
$2.36 /

+0.055 (+2.39%)

VCNX Vaccinex
$4.81 /

+0.86 (+21.77%)

SYNH Syneos Health
$57.99 /

+1.58 (+2.80%)

ETNB 89bio
$33.16 /

+0.78 (+2.41%)

COO Cooper Companies
$288.19 /

-1.02 (-0.35%)

CIEN Ciena
$54.81 /

-0.17 (-0.31%)

BILL Bill.com
$90.35 /

+0.66 (+0.74%)

APRE Aprea Therapeutics
$29.35 /

-0.12 (-0.41%)

ALNY Alnylam
$161.08 /

-1.25 (-0.77%)

ADPT Adaptive Biotechnologies
$47.00 /

+1.04 (+2.26%)

  • 08
    Jul
  • 11
    Jun
  • 24
    Jan
  • 12
    Dec
  • 11
    Nov
  • 03
    Oct
SYNH Syneos Health
$57.99 /

+1.58 (+2.80%)

CIEN Ciena
$54.81 /

-0.17 (-0.31%)

WTI W&T Offshore
$2.36 /

+0.055 (+2.39%)

VCNX Vaccinex
$4.81 /

+0.86 (+21.77%)

ETNB 89bio
$33.16 /

+0.78 (+2.41%)

COO Cooper Companies
$288.19 /

-1.02 (-0.35%)

CIEN Ciena
$54.81 /

-0.17 (-0.31%)

BILL Bill.com
$90.35 /

+0.66 (+0.74%)

ADPT Adaptive Biotechnologies
$47.00 /

+1.04 (+2.26%)

WTI W&T Offshore
$2.36 /

+0.055 (+2.39%)

CIEN Ciena
$54.81 /

-0.17 (-0.31%)

BILL Bill.com
$90.35 /

+0.66 (+0.74%)

Hot Stocks
Alnylam announces UK MHRA grants early access to lumasiran » 07:34
07/13/20
07/13
07:34
07/13/20
07:34
ALNY

Alnylam

$162.33 /

+3.48 (+2.19%)

Alnylam announced that…

Alnylam announced that the UK's Medicines and Healthcare Products Regulatory Agency, or MHRA, has granted lumasiran, an investigational RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1, or PH1, a positive scientific opinion through the Early Access to Medicines Scheme, or EAMS. With this decision, eligible PH1 patients in the UK, many of whom are children, can gain access to lumasiran before the drug is granted marketing authorization by the European Commission, or EC. The aim of EAMS is to provide early availability of innovative, unlicensed medicines to UK patients who have a high degree of unmet clinical need. The medicines included in the scheme are those that are intended to treat, diagnose or prevent seriously debilitating or life-threatening conditions where there are no adequate treatment options. PH1 is an ultra-rare orphan disease characterized by excessive oxalate production, which can lead to end-stage kidney disease, or ESKD, and other systemic complications.

ShowHide Related Items >><<
ALNY Alnylam
$162.33 /

+3.48 (+2.19%)

ALNY Alnylam
$162.33 /

+3.48 (+2.19%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
ALNY Alnylam
$162.33 /

+3.48 (+2.19%)

Over a week ago
Hot Stocks
Alnylam enters partnership with Taiba Group » 08:02
07/08/20
07/08
08:02
07/08/20
08:02
ALNY

Alnylam

$159.84 /

+7.41 (+4.86%)

Alnylam Pharmaceuticals…

Alnylam Pharmaceuticals and taiba Middle East announced that they have formed a Distribution Agreement for both ONPATTRO and GIVLAARI, the first-ever commercialized RNAi therapeutics, as well as another late-stage therapy in development for Primary Hyperoxaluria Type 1. The companies said in a release, "The Agreement between Alnylam and taiba will initially cover the Gulf states, including the Kingdom of Saudi Arabia, Kuwait, Bahrain, Qatar, Oman and the United Arab Emirates. It includes ONPATTRO, approved in the European Union in August 2018 for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy; GIVLAARI, approved in the EU in March 2020 for the treatment of acute hepatic porphyria (AHP); and lumasiran, a late-stage investigational RNAi therapeutic for the treatment of Primary Hyperoxaluria Type 1."

ShowHide Related Items >><<
ALNY Alnylam
$159.84 /

+7.41 (+4.86%)

ALNY Alnylam
$159.84 /

+7.41 (+4.86%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
ALNY Alnylam
$159.84 /

+7.41 (+4.86%)

ALNY Alnylam
$159.84 /

+7.41 (+4.86%)

Hot Stocks
Alnylam presents new data from OLE period of ENVISION study » 09:21
06/30/20
06/30
09:21
06/30/20
09:21
ALNY

Alnylam

$148.02 /

-3.655 (-2.41%)

Alnylam announced the…

Alnylam announced the presentation of new data from the open-label extension, or OLE, period of the ENVISION Phase 3 study. The results were presented during a webinar hosted by Alnylam. In an interim analysis of the OLE period, givosiran, which is approved in the U.S. and EU and marketed as Givlaari, demonstrated sustained efficacy and safety through 12 months of treatment, with evidence for potentially improved efficacy over time. The ENVISION Phase 3 study evaluated the efficacy and safety of givosiran in patients with AHP. As previously reported and recently published in the New England Journal of Medicine, givosiran met the primary endpoint in the 6-month double-blind, or DB, period, with a 74% mean reduction in the annualized rate of composite porphyria attacks, or AAR, that required hospitalization, urgent healthcare visit or intravenous hemin administration at home, and a median AAR of 1.0. Givosiran also demonstrated an acceptable safety and tolerability profile in this unmet need indication. Upon completion of dosing in the DB period, all eligible patients enrolled in the OLE period of the trial to receive monthly givosiran at either 2.5 mg/kg or 1.25 mg/kg. A dose of 1.25 mg/kg was initially studied in some patients to generate additional data at a lower dose level; all patients enrolled in the OLE period are now in the process of transitioning to the 2.5 mg/kg dose level, due to evidence for increased efficacy at the higher dose. Results at 12 months showed that continued givosiran treatment led to sustained AAR reduction in the OLE period with a median AAR of 0.0. The proportion of attack-free patients receiving givosiran increased from 50% in the DB period to 61.7% in the first six months of the OLE period. Sustained lowering of aminolevulinic acid and porphobilinogen in givosiran patients in the OLE period was accompanied by durable reductions in hemin use, lower levels of patient-reported daily worst pain and ongoing improvements in patient-reported quality of life and ability to function. Patients who crossed over from placebo in the DB period to givosiran in the OLE period experienced a mean reduction in AAR of 76%, similar to that experienced by givosiran patients in the DB period. Moreover, placebo crossover patients had reductions in hemin use and lower levels of patient-reported daily worst pain in the OLE period, consistent with the reductions observed in givosiran patients during the DB period. The safety profile of givosiran in the OLE period was consistent with that observed in the DB period, and there were no new safety findings. In the combined DB and OLE periods, as of July 23, 2019, the most common related adverse events, or AEs, on givosiran were injection site reactions, nausea and fatigue. Serious AEs included chronic kidney disease in two patients during the DB period and urinary tract infection in two patients during the OLE period. In the combined DB and OLE periods, hepatic and renal AEs were reported in 16 patients and 10 patients, respectively. The majority of AEs were mild or moderate in severity, and there were no new treatment discontinuations due to AEs in the OLE period and no deaths.

ShowHide Related Items >><<
ALNY Alnylam
$148.02 /

-3.655 (-2.41%)

ALNY Alnylam
$148.02 /

-3.655 (-2.41%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
ALNY Alnylam
$148.02 /

-3.655 (-2.41%)

ALNY Alnylam
$148.02 /

-3.655 (-2.41%)

Hot Stocks
Intercept plunges, drags down some NASH peers after CRL from FDA » 07:26
06/29/20
06/29
07:26
06/29/20
07:26
ICPT

Intercept

$77.56 /

-2.09 (-2.62%)

, CBAY

CymaBay

$3.74 /

-0.11 (-2.86%)

, NGM

NGM Biopharmaceuticals

$22.37 /

-0.53 (-2.31%)

, MDGL

Madrigal Pharmaceuticals

$108.04 /

-2.46 (-2.23%)

, NVO

Novo Nordisk

$66.03 /

-1.18 (-1.76%)

, GNFT

Genfit

$5.57 /

-0.42 (-7.01%)

, LLY

Eli Lilly

$162.91 /

-0.09 (-0.06%)

, ALNY

Alnylam

$151.68 /

-4.765 (-3.05%)

Shares of Intercept…

Shares of Intercept Pharmaceuticals (ICPT) have plunged in early morning trading after the company announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for obeticholic acid for the treatment of fibrosis due to nonalcoholic steatohepatitis, or NASH. Based on the data the FDA has reviewed to date, the Agency has determined that the predicted benefit of OCA based on a surrogate histopathologic endpoint remains uncertain and does not sufficiently outweigh the potential risks to support accelerated approval for the treatment of patients with liver fibrosis due to NASH, Intercept tells investors. Following the announcement, shares of Intercept are down $25.82, or 33%, to $51.67 in pre-market trading. A number of other companies working on NASH treatments are also moving lower, with CymaBay (CBAY) down about 3% and NGM Biopharmaceuticals (NGM) fractionally lower. Other companies exploring NASH treatments include Madrigal Pharmaceuticals (MDGL), Novo Nordisk (NVO), Genfit (GNFT), Eli Lilly (LLY), and Alnylam Pharmaceuticals (ALNY).

ShowHide Related Items >><<
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

MDGL Madrigal Pharmaceuticals
$108.04 /

-2.46 (-2.23%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

GNFT Genfit
$5.57 /

-0.42 (-7.01%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

06/25/20 H.C. Wainwright
Intercept initiated with a Neutral at H.C. Wainwright
06/04/20 BMO Capital
Intercept initiated with an Outperform at BMO Capital
05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

06/22/20 B. Riley FBR
CymaBay risk/reward favorable into FDA engagement, says B. Riley FBR
05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
05/12/20 B. Riley FBR
CymaBay upgraded to Buy from Neutral at B. Riley FBR
NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

06/04/20 BMO Capital
NGM Biopharmaceuticals initiated with an Outperform at BMO Capital
05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
MDGL Madrigal Pharmaceuticals
$108.04 /

-2.46 (-2.23%)

06/04/20 BMO Capital
Madrigal Pharmaceuticals initiated with a Market Perform at BMO Capital
05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
GNFT Genfit
$5.57 /

-0.42 (-7.01%)

06/25/20 BofA
Genfit's NASH program 'all but done,' says BofA, initiating with an Underperform
06/25/20 BofA
Genfit initiated with an Underperform at BofA
05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

MDGL Madrigal Pharmaceuticals
$108.04 /

-2.46 (-2.23%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

  • 11
    Dec
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

GNFT Genfit
$5.57 /

-0.42 (-7.01%)

ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

Conference/Events
BofA to hold a virtual conference » 04:55
06/24/20
06/24
04:55
06/24/20
04:55
ALXN

Alexion

$115.44 /

-1.47 (-1.26%)

, JNJ

Johnson & Johnson

$142.86 /

-0.52 (-0.36%)

, NBIX

Neurocrine

$127.61 /

+0.17 (+0.13%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SRPT

Sarepta

$168.86 /

-3 (-1.75%)

, ALNY

Alnylam

$152.00 /

-0.91 (-0.60%)

, BTAI

BioXcel Therapeutics

$58.53 /

+1.57 (+2.76%)

Napa Healthcare Virtual…

Napa Healthcare Virtual Conference will be held on June 22-24.

ShowHide Related Items >><<
SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

06/18/20 JPMorgan
Neurocrine price target raised to $134 from $122 at JPMorgan
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
06/17/20 H.C. Wainwright
Neurocrine price target raised to $131 from $125 at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
SRPT Sarepta
$168.86 /

-3 (-1.75%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

06/05/20 Guggenheim
Guggenheim starts BioXcel Therapeutics at Buy on optimistic view of lead asset
06/04/20 Guggenheim
BioXcel Therapeutics initiated with a Buy at Guggenheim
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
BioXcel Therapeutics initiated with a Buy at BofA
SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

Conference/Events
BofA to hold a virtual conference » 04:55
06/23/20
06/23
04:55
06/23/20
04:55
ALXN

Alexion

$116.91 /

-2.36 (-1.98%)

, JNJ

Johnson & Johnson

$143.38 /

-0.63 (-0.44%)

, NBIX

Neurocrine

$127.44 /

-0.65 (-0.51%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SRPT

Sarepta

$171.86 /

+3.36 (+1.99%)

, ALNY

Alnylam

$152.91 /

+3.23 (+2.16%)

, BTAI

BioXcel Therapeutics

$56.96 /

+4.27 (+8.10%)

Napa Healthcare Virtual…

Napa Healthcare Virtual Conference will be held on June 22-24.

ShowHide Related Items >><<
SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

06/18/20 JPMorgan
Neurocrine price target raised to $134 from $122 at JPMorgan
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
06/17/20 H.C. Wainwright
Neurocrine price target raised to $131 from $125 at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

06/05/20 Guggenheim
Guggenheim starts BioXcel Therapeutics at Buy on optimistic view of lead asset
06/04/20 Guggenheim
BioXcel Therapeutics initiated with a Buy at Guggenheim
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
BioXcel Therapeutics initiated with a Buy at BofA
SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

Conference/Events
BofA to hold a virtual conference » 08:54
06/22/20
06/22
08:54
06/22/20
08:54
ALXN

Alexion

$119.27 /

+3 (+2.58%)

, JNJ

Johnson & Johnson

$144.01 /

+0.46 (+0.32%)

, NBIX

Neurocrine

$128.09 /

+7.06 (+5.83%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SRPT

Sarepta

$168.50 /

+3.27 (+1.98%)

, ALNY

Alnylam

$149.68 /

+7.67 (+5.40%)

, BTAI

BioXcel Therapeutics

$52.69 /

-2.16 (-3.94%)

Napa Healthcare Virtual…

Napa Healthcare Virtual Conference will be held on June 22-24.

ShowHide Related Items >><<
SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$128.09 /

+7.06 (+5.83%)

JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

BTAI BioXcel Therapeutics
$52.69 /

-2.16 (-3.94%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

ALNY Alnylam
$149.68 /

+7.67 (+5.40%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
NBIX Neurocrine
$128.09 /

+7.06 (+5.83%)

06/18/20 JPMorgan
Neurocrine price target raised to $134 from $122 at JPMorgan
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
06/17/20 H.C. Wainwright
Neurocrine price target raised to $131 from $125 at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
06/08/20 Piper Sandler
Sarepta limb-girdle muscular dystrophy data 'look great,' says Piper Sandler
ALNY Alnylam
$149.68 /

+7.67 (+5.40%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
BTAI BioXcel Therapeutics
$52.69 /

-2.16 (-3.94%)

06/05/20 Guggenheim
Guggenheim starts BioXcel Therapeutics at Buy on optimistic view of lead asset
06/04/20 Guggenheim
BioXcel Therapeutics initiated with a Buy at Guggenheim
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
BioXcel Therapeutics initiated with a Buy at BofA
SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$128.09 /

+7.06 (+5.83%)

JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

BTAI BioXcel Therapeutics
$52.69 /

-2.16 (-3.94%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

ALNY Alnylam
$149.68 /

+7.67 (+5.40%)

SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

RHHBY Roche
$0.00 /

+ (+0.00%)

JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

ALNY Alnylam
$149.68 /

+7.67 (+5.40%)

SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$128.09 /

+7.06 (+5.83%)

JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

BTAI BioXcel Therapeutics
$52.69 /

-2.16 (-3.94%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

JNJ Johnson & Johnson
$144.01 /

+0.46 (+0.32%)

BTAI BioXcel Therapeutics
$52.69 /

-2.16 (-3.94%)

ALXN Alexion
$119.27 /

+3 (+2.58%)

Over a month ago
Conference/Events
Goldman Sachs to hold a virtual conference » 08:47
06/11/20
06/11
08:47
06/11/20
08:47
HUM

Humana

$392.51 /

+1.51 (+0.39%)

, DTIL

Precision BioSciences

$8.30 /

-0.31 (-3.60%)

, CHNG

Change Healthcare

$11.85 /

-0.37 (-3.03%)

, ALKS

Alkermes

$16.77 /

-0.51 (-2.95%)

, ALNY

Alnylam

$129.96 /

+0.09 (+0.07%)

, HCAT

Health Catalyst

$28.79 /

+0.1 (+0.35%)

, KLDO

Kaleido Biosciences

$7.44 /

-0.155 (-2.04%)

, ZEAL

Zealand Pharma

$39.08 /

+0.48 (+1.24%)

, GOSS

Gossamer Bio

$12.38 /

-0.23 (-1.82%)

, MRNA

Moderna

$59.88 /

+1.58 (+2.71%)

, ORTX

Orchard Therapeutics

$7.99 /

+0.23 (+2.96%)

, BMY

Bristol-Myers

$60.15 /

-0.75 (-1.23%)

, ADVM

Adverum Biotechnologies

$23.85 /

+0.44 (+1.88%)

, BCYC

Bicycle Therapeutics

$17.35 /

+0.15 (+0.87%)

, ESPR

Esperion

$46.64 /

-1.01 (-2.12%)

, PHAT

Phathom Pharmaceuticals

$50.33 /

-1.45 (-2.80%)

, INSP

Inspire Medical

$85.53 /

-3.11 (-3.51%)

, UBX

Unity Biotechnology

$8.88 /

+0.32 (+3.74%)

, PHG

Philips

$46.76 /

-0.39 (-0.83%)

, ATRA

Atara Biotherapeutics

$9.91 /

-0.455 (-4.39%)

41st Annual Global…

41st Annual Global Healthcare Virtual Conference will be held on June 9-11. Webcast Link

ShowHide Related Items >><<
ZEAL Zealand Pharma
$39.08 /

+0.48 (+1.24%)

UBX Unity Biotechnology
$8.88 /

+0.32 (+3.74%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

ESPR Esperion
$46.64 /

-1.01 (-2.12%)

DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

ATRA Atara Biotherapeutics
$9.91 /

-0.455 (-4.39%)

ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

06/05/20 Goldman Sachs
Humana initiated with a Buy at Goldman Sachs
06/01/20 Stephens
Molina Healthcare price target raised to $215 from $202 at Stephens
05/21/20 SunTrust
SunTrust raises price targets across select Healthcare Services names
05/04/20 Mizuho
Humana price target raised to $420 from $405 at Mizuho
DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

06/10/20 KeyBanc
Inovalon displaces Change Healthcare in Priority Health deal, says KeyBanc
06/09/20 Piper Sandler
Piper Sandler says buy Change Healthcare, sell Inovalon
04/13/20 SVB Leerink
Change Healthcare initiated with an Outperform at SVB Leerink
03/26/20 Cowen
Cowen sees three healthcare IT names poised for rebound
ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

04/30/20 H.C. Wainwright
Alkermes price target lowered to $23 from $25 at H.C. Wainwright
04/29/20 Piper Sandler
Alkermes price target lowered to $21 from $22 at Piper Sandler
04/29/20 Stifel
Alkermes price target lowered to $17 from $20 at Stifel
02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

05/27/20 Piper Sandler
Piper bullish on post pandemic opportunities for Health Catalyst
05/15/20
Fly Intel: Top five analyst initiations
05/15/20 Guggenheim
Guggenheim sees Health Catalyst at attractive entry point, starts at Buy
05/15/20 Guggenheim
Health Catalyst initiated with a Buy at Guggenheim
KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Kaleido to Equal Weight amid delays for key programs
05/21/20 Morgan Stanley
Kaleido downgraded to Equal Weight from Overweight at Morgan Stanley
ZEAL Zealand Pharma
$39.08 /

+0.48 (+1.24%)

03/10/20 Morgan Stanley
Zealand Pharma EPS estimates cut at Morgan Stanley
11/19/19 Jefferies
Zealand Pharma downgraded to Hold from Buy at Jefferies
11/15/19 Needham
Zealand Pharma price target raised to $42 from $32 at Needham
10/15/19
Fly Intel: Top five analyst upgrades
GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

05/29/20 Piper Sandler
Piper says Gossamer's GB1275 well tolerated, early activity signs 'promising'
05/20/20 SVB Leerink
Gossamer Bio price target raised to $36 from $27 at SVB Leerink
04/22/20 Piper Sandler
Gossamer Bio initiated with an Overweight at Piper Sandler
02/27/20 Barclays
Gossamer Bio initiated with an Overweight at Barclays
MRNA Moderna
$59.88 /

+1.58 (+2.71%)

06/08/20 Barclays
Moderna initiated with an Overweight at Barclays
06/02/20 Piper Sandler
Piper reiterates Overweight rating, $100 target for Moderna after Science Day
06/02/20 BofA
Moderna price target lowered to $75 from $80 at BofA
06/01/20 Goldman Sachs
Goldman keeps $105 target after Moderna COVID vaccine moves to Phase 2
ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

05/22/20 JPMorgan
Orchard Therapeutics price target lowered to $17 from $26 at JPMorgan
09/17/19
Fly Intel: Top five analyst initiations
09/17/19
Guggenheim bullish on Orchard Therapeutics, initiates with a Buy
09/17/19 Guggenheim
Orchard Therapeutics initiated with a Buy at Guggenheim
BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

05/29/20 Piper Sandler
Adverum Biotechnologies price target raised to $25 from $20 at Piper Sandler
05/12/20 RBC Capital
Adverum Biotechnologies initiated with an Outperform at RBC Capital
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
ESPR Esperion
$46.64 /

-1.01 (-2.12%)

05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
04/20/20 JMP Securities
JMP reiterates $191 price target on Esperion after Japan partnership
04/16/20 Northland
Esperion price target lowered to $42 from $60 at Northland
04/01/20
Fly Intel: Top five analyst initiations
PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

11/19/19 Evercore ISI
Phathom Pharmaceuticals initiated with an Outperform at Evercore ISI
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/19/19 Jefferies
Phathom Pharmaceuticals initiated with a Buy at Jefferies
INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

05/26/20 Wells Fargo
Inspire Medical price target raised to $95 from $81 at Wells Fargo
05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Lake Street
Inspire Medical initiated with a Buy at Lake Street
05/06/20 Guggenheim
Inspire Medical price target raised to $90 from $80 at Guggenheim
UBX Unity Biotechnology
$8.88 /

+0.32 (+3.74%)

12/13/19
Unity Biotechnology management to meet with Mizuho
12/12/19 Cantor Fitzgerald
Unity Biotechnology assumed with an Overweight at Cantor Fitzgerald
PHG Philips
$46.76 /

-0.39 (-0.83%)

04/22/20 Morgan Stanley
Philips price target lowered to EUR 45 from EUR 50 at Morgan Stanley
04/21/20 JPMorgan
Philips price target raised to EUR 36.80 from EUR 33.90 at JPMorgan
04/07/20 JPMorgan
Philips price target lowered to EUR 33.90 from EUR 43.10 at JPMorgan
03/24/20 DZ Bank
Philips upgraded to Buy from Hold at DZ Bank
ATRA Atara Biotherapeutics
$9.91 /

-0.455 (-4.39%)

05/22/20 Mizuho
Atara multiple sclerosis data looks 'awesome' at first glance, says Mizuho
04/23/20 Citi
Atara Biotherapeutics upgraded to Buy on valuation at Citi
04/23/20 Citi
Atara Biotherapeutics upgraded to Buy from Neutral at Citi
11/08/19 JPMorgan
Atara Biotherapeutics downgraded to on lack of catalysts at JPMorgan
ZEAL Zealand Pharma
$39.08 /

+0.48 (+1.24%)

UBX Unity Biotechnology
$8.88 /

+0.32 (+3.74%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

ESPR Esperion
$46.64 /

-1.01 (-2.12%)

DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

ATRA Atara Biotherapeutics
$9.91 /

-0.455 (-4.39%)

ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

ESPR Esperion
$46.64 /

-1.01 (-2.12%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

Hot Stocks
Alnylam announces ENVISION study results published in NEJM » 17:13
06/10/20
06/10
17:13
06/10/20
17:13
ALNY

Alnylam

$129.96 /

+0.09 (+0.07%)

Alnylam announced that…

Alnylam announced that pivotal results from the ENVISION Phase 3 study of givosiran, an RNAi therapeutic targeting aminolevulinic acid synthase 1, or ALAS1, for the treatment of acute hepatic porphyria, or AHP, were published online in the New England Journal of Medicine, or NEJM. Givlaari was approved by the FDA for the treatment of adults with AHP in November 2019, marking the first ever approval of a GalNAc-conjugate RNAi therapeutic-a landmark in the advancement of precision genetic medicines. It also received marketing authorization from the European Commission in March for the treatment of AHP in adults and adolescents aged 12 years and older. The full manuscript will appear in the June 11 issue of NEJM. The data reported in the ENVISION Phase 3 study publication demonstrated that RNAi-mediated targeting of liver ALAS1 by givosiran led to sustained reductions in aminolevulinic acid, or ALA, and porphobilinogen, or PBG, the toxic heme synthesis intermediates believed to be causal for the disease manifestations of AHP. Relative to placebo, treatment with givosiran resulted in a significant and clinically meaningful reduction of 74% in the primary endpoint of the annualized rate of composite porphyria attacks, or AAR, defined as those attacks requiring hospitalization, urgent healthcare visit, or intravenous hemin administration at home, in patients with acute intermittent porphyria, or AIP, the most common form of AHP, over six months. Improvements were also observed in a number of secondary endpoints, including reductions in urinary ALA and PBG levels, days of intravenous hemin use and daily worst pain. Additionally, in all patients with AHP, mean AAR was significantly reduced by 73% relative to placebo. Patients treated with givosiran also reported favorable effects on exploratory endpoints related to use of analgesics, overall health status and daily functioning. The most common adverse events observed in the givosiran group during the 6-month double-blind, or DB, period were nausea and injection site reactions. Other adverse events seen more frequently in patients treated with givosiran compared to placebo included chronic kidney disease, fatigue, alanine aminotransferase increase, glomerular filtration rate decrease and rash. Upon completion of dosing in the six-month DB period, 93 out of 94 patients enrolled in the ENVISION open-label extension, or OLE, period to receive givosiran on an ongoing basis.

ShowHide Related Items >><<
ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.